These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1725234)

  • 1. HIV-1 neutralizing antibody and approaches to the envelope diversity problem.
    Matthews TJ; Langlois AJ; Butto S; Bolognesi D; Javaherian K
    Adv Exp Med Biol; 1991; 303():23-6. PubMed ID: 1725234
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein.
    Zaghouani H; Hall B; Shah H; Bona C
    Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238
    [No Abstract]   [Full Text] [Related]  

  • 3. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to env epitopes and relationship to neutralization.
    Cheingsong-Popov R; Callow D; Beddows S; Shaunak S; Wasi C; Kaleebu P; Gilks C; Petrascu IV; Garaev MM; Watts DM
    J Infect Dis; 1992 Feb; 165(2):256-61. PubMed ID: 1370525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusion-competent vaccines: broad neutralization of primary isolates of HIV.
    LaCasse RA; Follis KE; Trahey M; Scarborough JD; Littman DR; Nunberg JH
    Science; 1999 Jan; 283(5400):357-62. PubMed ID: 9888845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunology. Close to the edge: neutralizing the HIV-1 envelope.
    Nabel GJ
    Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295
    [No Abstract]   [Full Text] [Related]  

  • 9. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.
    Yang X; Kurteva S; Lee S; Sodroski J
    J Virol; 2005 Mar; 79(6):3500-8. PubMed ID: 15731244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.
    Frost SD; Wrin T; Smith DM; Kosakovsky Pond SL; Liu Y; Paxinos E; Chappey C; Galovich J; Beauchaine J; Petropoulos CJ; Little SJ; Richman DD
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18514-9. PubMed ID: 16339909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
    Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
    J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral immune responses to homologous envelope peptides in vaccinees and lab workers infected with HIV.
    Pincus SH; Messer K
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1347. PubMed ID: 1466954
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.
    Quiñones-Kochs MI; Buonocore L; Rose JK
    J Virol; 2002 May; 76(9):4199-211. PubMed ID: 11932385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2.
    Skott P; Achour A; Norin M; Thorstensson R; Björling E
    Viral Immunol; 1999; 12(1):79-88. PubMed ID: 10333245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
    Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
    J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies.
    Montefiori DC; Evans TG
    AIDS Res Hum Retroviruses; 1999 May; 15(8):689-98. PubMed ID: 10357464
    [No Abstract]   [Full Text] [Related]  

  • 19. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody neutralization and escape by HIV-1.
    Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
    Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.